Cushing's Disease Market Project to Grow at a CAGR of 5.90% Through 2034, DelveInsight Finds

The Cushing's Disease market was valued at approximately USD 1 billion in the 7MM (United States, EU4, UK, and Japan) in 2025 and is projected to grow at a CAGR of 5.90% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Cushing's Disease landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Cushing's Disease market is increasingly guided by the development of selective cortisol modulators and enzymatic inhibitors. Among current therapies for Cushing's Disease, the highest revenue in 2024 was generated by Mifepristone (KORLYM and generics) in the US, establishing a strong market foothold for glucocorticoid receptor modulators.

Cushing's Disease accounts for approximately 80% of all endogenous Cushing's Syndrome cases, making it the most common cause of endogenous hypercortisolism. Based on DelveInsight's assessment in 2024, the 7MM had approximately 37,000 diagnosed prevalent cases of Cushing's Disease. The incidence of Cushing's Disease is estimated to range between 1 out of 588,235 to 833,333 individuals per year, with an overall incidence of Cushing's Syndrome (all causes considered) ranging between 1 out of 12,658 to 17,544 individuals per year. The mean age at diagnosis is 40 years, and there is a significant female predominance with a female-to-male ratio of 3:1.

DelveInsight's report, "Cushing's Disease Market Insights, Epidemiology, and Market Forecast- 2034", provides a comprehensive analysis of the Cushing's Disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Cushing's Disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Cushing's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, download the Cushing's Disease Market Report

Some of the key facts of the Cushing's Disease Market Report:

• Key Cushing's Disease Companies: Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others
• Key Cushing's Disease Therapies: Mifepristone (KORLYM), Osilodrostat (Isturisa), Relacorilant, Levoketoconazole, Mitotane, Etomidate, and others
• The Cushing's Disease market is expected to surge due to the disease's increasing diagnosis and awareness during the forecast period. Furthermore, launching various multiple-stage Cushing's Disease pipeline products will significantly revolutionize the Cushing's Disease market dynamics.

Cushing's Disease Overview

Cushing's Disease is a rare endocrine disorder characterized by excessive cortisol production resulting from a pituitary adenoma that secretes adrenocorticotropic hormone (ACTH). This distinct etiology makes Cushing's Disease the most common cause of endogenous Cushing's Syndrome, accounting for approximately 80% of all endogenous hypercortisolism cases. The disease manifests with multiple systemic complications, including hypertension, metabolic dysfunction, cardiovascular complications, and psychological impairment. Cushing's Disease typically presents with a significant female predominance and occurs most commonly during the fourth decade of life. Early diagnosis through biochemical and imaging studies, coupled with personalized treatment approaches including pharmacotherapy and surgical intervention, improves patient outcomes.

Key Trends in Cushing's Disease Therapeutics Market

• Selective Cortisol Modulation: Increasing adoption of glucocorticoid receptor modulators such as relacorilant that offer targeted cortisol regulation with improved safety profiles
• Enzymatic Inhibition Advances: Development of next-generation 11-beta-hydroxylase inhibitors and ketoconazole stereoisomers for enhanced cortisol suppression
• Precision Medicine & Biomarker Discovery: Enhanced molecular diagnostics and genetic profiling to identify specific pituitary pathways and tailor treatment strategies
• Pipeline Innovation: Development of novel mechanisms of action including bispecific antibodies and targeted immunotherapies to overcome resistance and enhance efficacy
• Patient-Centric Outcomes: Growing emphasis on cardiovascular and metabolic improvement alongside cortisol normalization
• Digital Health Integration: Use of remote monitoring and telemedicine to optimize treatment adherence and long-term management of Cushing's Disease patients

Cushing's Disease Epidemiology

The report on Cushing's Disease epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on the proportion of Cushing's Disease within the broader Cushing's Syndrome spectrum. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of Cushing's Disease and plan targeted interventions, research, and treatment strategies.

Cushing's Disease Epidemiology Segmentation

The Cushing's Disease market report proffers epidemiological analysis for the study period 2025–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Cushing's Disease
• Diagnosed Cases of Cushing's Disease by gender
• Age-specific Diagnosed Cases of Cushing's Disease
• Regional Distribution of Cushing's Disease Cases

Download the report to understand which factors are driving Cushing's Disease epidemiology trends @ Cushing's Disease Epidemiology Analysis

Recent Developments in the Cushing's Disease Treatment Landscape

• In May 2025, Corcept Therapeutics announced that the FDA assigned a PDUFA target action date of December 30, 2025, for relacorilant to treat patients with endogenous hypercortisolism (Cushing's disease). Relacorilant has shown significant cardiometabolic benefits in Phase III trials including blood pressure reductions.
• In April 2025, the FDA approved the label expansion for osilodrostat (ISTURISA) to treat endogenous hypercortisolemia in adults with Cushing’s syndrome. This expanded indication covers patients who cannot undergo surgery or where surgery was not curative, backed by positive clinical trial results (LINC 4 Phase 3).
• In March 2025, Corcept Therapeutics announced that the FDA had accepted the New Drug Application (NDA) for relacorilant, assigning a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025, for treating patients with endogenous hypercortisolism. Relacorilant is a selective glucocorticoid receptor modulator designed to normalize cortisol levels without affecting other hormone receptors.
• Emerging Pipeline Programs: Leading companies including Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, and Stero Therapeutics are advancing novel Cushing's Disease therapies targeting distinct mechanisms of action, including ACTH antagonists and alternative enzymatic pathways for cortisol inhibition.

Cushing's Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cushing's Disease market or expected to get launched during the study period. The analysis covers Cushing's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cushing's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cushing's Disease Therapies and Key Companies:

• Relacorilant: Corcept Therapeutics
• Levoketoconazole: Cortendo AB
• Osilodrostat (Isturisa): Novartis
• Mifepristone (KORLYM): Corcept Therapeutics
• Mitotane: Various manufacturers, and others.

To know more about Cushing's Disease companies working in the treatment market and their competitive advantages, visit @ Cushing's Disease Competitive Landscape

Cushing's Disease Market Drivers

• Increasing prevalence and diagnosis of Cushing's Disease with improved awareness among healthcare providers
• Growing demand for selective cortisol modulators offering improved safety and efficacy profiles
• Advancements in diagnostic technologies enabling earlier detection and accurate differentiation of Cushing's Disease from other causes of hypercortisolism
• Rising healthcare expenditure and government initiatives supporting rare disease treatment
• Development of combination therapies improving patient outcomes and cardiovascular risk reduction
• Enhanced understanding of disease pathophysiology driving targeted drug development

Cushing's Disease Market Barriers

• High cost of novel targeted therapies limiting patient access and adoption rates
• Complex diagnostic pathways requiring specialized endocrinology expertise delaying disease confirmation
• Limited awareness of Cushing's Disease in primary care settings leading to diagnostic delays
• Variability in diagnostic criteria and biochemical test standardization across regions
• Side effects and safety concerns associated with existing treatments affecting patient compliance
• Reimbursement challenges and variable market access policies across different healthcare systems

Scope of the Cushing's Disease Market Report

• Study Period: 2025–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Cushing's Disease Companies: Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others
• Key Cushing's Disease Therapies: Relacorilant, Levoketoconazole, Osilodrostat (Isturisa), Mifepristone (KORLYM), Mitotane, Etomidate, and others
• Cushing's Disease Therapeutic Assessment: Cushing's Disease current marketed and Cushing's Disease emerging therapies
• Cushing's Disease Market Dynamics: Cushing's Disease market drivers and Cushing's Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cushing's Disease Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement

Discover more about therapies set to grab major Cushing's Disease market share @ Cushing's Disease Treatment landscape